GF
IMCR icon

Gates Foundation’s Immunocore IMCR Stock Holding History

Gates Foundation’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-576,923
Closed -$37.5M – 6
2024
Q1 		$37.5M Hold
576,923
– – 44.58% 1
2023
Q4 		$39.4M Hold
576,923
– – 43.85% 1
2023
Q3 		$29.9M Hold
576,923
– – 35.7% 1
2023
Q2 		$34.6M Hold
576,923
– – 27.53% 2
2023
Q1 		$28.5M Hold
576,923
– – 25.19% 2
2022
Q4 		$32.9M Hold
576,923
– – 25.37% 2
2022
Q3 		$27.1M Hold
576,923
– – 21.42% 2
2022
Q2 		$21.5M Hold
576,923
– – 16.53% 4
2022
Q1 		$17.2M Hold
576,923
– – 9.25% 6
2021
Q4 		$55.8M Hold
576,923
– – 16.93% 2
2021
Q3 		$21.4M Hold
576,923
– – 6.26% 5
2021
Q2 		$23M Hold
576,923
– – 3.53% 4
2021
Q1 		$24.6M Buy
+576,923
New +$25.7M 4.02% 4

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Gates Foundation's IMCR Position: Q2 2024 in Review

Gates Foundation sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 576,923 shares — an estimated $37.5M sold.

Gates Foundation first reported a position in IMCR in Q1 2021 and held it in 13 quarters. The position peaked at $55.8M in Q4 2021. 139 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • Gates Foundation reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • Gates Foundation sold 576,923 Immunocore shares in Q2 2024, an estimated $37.5M.
  • Gates Foundation first reported a position in Immunocore in Q1 2021 and held it in 13 quarters.
  • Gates Foundation's Immunocore position peaked at $55.8M in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Gates Foundation's 13F filing for Q2 2024, filed 14 Aug 2024.